Answers are grounded in this paper and cite their sources.
Atherosclerosis is a leading cause of cardiovascular morbidity and mortality, and the gut microbiota is a potential therapeutic target. Antiruisi (ATRS) is a fixed-ratio combination of natural-product-derived active ingredients. In this study, 24 male ApoE−/− mice were assigned to normal chow, high-fat diet (HFD), HFD plus atorvastatin, or HFD plus ATRS groups (n = 6 per group) and treated for 12 weeks. ATRS improved serum lipid profiles, reduced atherosclerotic plaque area, and attenuated hepatic steatosis and lipid accumulation. ATRS also altered gut microbial composition, reduced circulating trimethylamine N-oxide levels and hepatic flavin-containing monooxygenase 3 expression, modulated the farnesoid X receptor, fibroblast growth factor 15, and cholesterol 7α-hydroxylase expression, and regulated p38 mitogen-activated protein kinase and nuclear factor-kappa B expression, as well as associated inflammatory marker levels. These findings suggest that ATRS attenuates atherosclerosis in HFD-fed ApoE−/− mice, with accompanying changes in gut microbiota composition and metabolic and inflammatory markers.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: